ArticleRespirology case reports2022
Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis.
Article in Respirology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- ANCA-Positive Small-Vessel Vasculitis Following SARS-CoV-2 Vaccination-A Systematic Review.Vaccines · 2024Review
- A case of rapidly progressive glomerulonephritis with double-positive anti-GBM antibody and MPO-ANCA after SARS-CoV-2 vaccination and relapse during 1 year follow-up.CEN case reports · 2024Article
- COVID-19 vaccine-associated vasculitis: A systematic review.SAGE open medicine · 2024Review
- New-onset ANCA-associated vasculitis presenting with neuropathy after COVID-19 infection: A case report and literature review.Clinical case reports · 2024Article
- New insights of antineutrophil cytoplasmic antibody-associated vasculitis from the perspective of COVID-19 vaccination.Clinical and experimental immunology · 2023Article
- Vaccine hesitancy is not increased in patients with ASIA (autoimmune/inflammatory syndrome induced by adjuvants) when compared to patients with vasculitis.Clinical rheumatology · 2023Article
- ANCA-associated vasculitis flare might be provoked by COVID-19 infection: a case report and a review of the literature.Clinical kidney journal · 2022Review
- Increased induction ofiScience · 2022Article
- COVID-19 vaccination precipitatingClinical kidney journal · 2022Article
- Review
- Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis.Respirology case reports · 2022Article
- Neutrophil Extracellular Traps, Sepsis and COVID-19 - A Tripod Stand.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory processes, such as an infection or drug reaction, can cause antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). Although quite rare, AAV may occur with SARS-coronavirus disease 2019 (COVID-19) antigenic exposure, either from infection or immunization. We present two cases of AAV: one that developed after COVID-19 infection presenting as diffuse alveolar haemorrhage and another that developed shortly after vaccination, presenting as granulomatous pulmonary nodules. Both patients improved with supportive care and immunosuppressive therapies. This adverse event appears to be a very rare complication of COVID-19 infection or vaccination. Early diagnosis of AAV is important because immunosuppressive therapy may improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.